Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 115 Gliosarcoma 53 Brain Neoplasms 53 Glioma 47 Central Nervous System Neoplasms 30 Astrocytoma 29 Melanoma 26 Oligodendroglioma 14 Neuroblastoma 10 Neoplasm Metastasis 9 Recurrence 7 Ependymoma 7 Sarcoma 6 Neoplasms 6 Carcinoma, Non-Small-Cell Lung 6 Skin Neoplasms 5 Sarcoma, Ewing 5 Lymphoma 5 Breast Neoplasms 5 Spinal Cord Neoplasms 4 Somatostatinoma 4 Neuroectodermal Tumors, Primitive, Peripheral 4 Medulloblastoma 4 Colorectal Neoplasms 4 Small Cell Lung Carcinoma 3 Lung Neoplasms 3 Gastrinoma 3 Carcinoma, Islet Cell 3 Uveal Melanoma 2 Rhabdomyosarcoma 2

Interventions

sargramostim 1 Vaccines 1 Temozolomide 1 Papillomavirus Vaccines 1 Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1 Granulocyte-Macrophage Colony-Stimulating Factor 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Tetanus × Temozolomide × Clear all

NCT03927222 2024-04-08

I-ATTAC

Duke University

Phase 2 Terminated

6 enrolled 7 charts

Glioblastoma, Tetanus

Data powered by HemOnc (CC BY 4.0) Colophon ⚡